JP2019507143A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507143A5 JP2019507143A5 JP2018543139A JP2018543139A JP2019507143A5 JP 2019507143 A5 JP2019507143 A5 JP 2019507143A5 JP 2018543139 A JP2018543139 A JP 2018543139A JP 2018543139 A JP2018543139 A JP 2018543139A JP 2019507143 A5 JP2019507143 A5 JP 2019507143A5
- Authority
- JP
- Japan
- Prior art keywords
- triazolo
- oxazepine
- thieno
- cancer
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCC1C(C(C)*C)*(C)CC(C)C1 Chemical compound CCC1C(C(C)*C)*(C)CC(C)C1 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662295271P | 2016-02-15 | 2016-02-15 | |
| US62/295,271 | 2016-02-15 | ||
| US201662393897P | 2016-09-13 | 2016-09-13 | |
| US62/393,897 | 2016-09-13 | ||
| PCT/US2017/017848 WO2017142881A1 (en) | 2016-02-15 | 2017-02-15 | Fused 1,4-oxazepines and related analogs as bet bromodomain inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507143A JP2019507143A (ja) | 2019-03-14 |
| JP2019507143A5 true JP2019507143A5 (enExample) | 2020-03-26 |
| JP6967522B2 JP6967522B2 (ja) | 2021-11-17 |
Family
ID=58191613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543139A Expired - Fee Related JP6967522B2 (ja) | 2016-02-15 | 2017-02-15 | Ｂｅｔブロモドメイン阻害剤としての融合１，４−オキサゼピンおよび関連類似体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11548899B2 (enExample) |
| EP (1) | EP3416969B1 (enExample) |
| JP (1) | JP6967522B2 (enExample) |
| CN (1) | CN109071562B (enExample) |
| AU (1) | AU2017219627B2 (enExample) |
| CA (1) | CA3014644A1 (enExample) |
| ES (1) | ES2882066T3 (enExample) |
| WO (1) | WO2017142881A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3036834A1 (en) * | 2016-09-13 | 2018-03-22 | The Regents Of The University Of Michigan | Fused 1,4-oxazepines as bet protein degraders |
| US11267822B2 (en) | 2017-09-13 | 2022-03-08 | The Regents Of The University Of Michigan | BET bromodomain protein degraders with cleavable linkers |
| CN115466315A (zh) * | 2021-06-10 | 2022-12-13 | 首都医科大学 | 抑制侵袭的1-咪唑-β-咔啉-3-甲酰-RGDS及制备,抗癌转移作用和应用 |
| CN116410205B (zh) * | 2021-12-29 | 2024-07-05 | 上海皓元生物医药科技有限公司 | 一种3-取代-9-甲基-噻吩并三唑并噁嗪类化合物的制备方法 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| WO1998011111A1 (en) | 1996-09-13 | 1998-03-19 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienotriazolodiazepine compounds and medicinal uses thereof |
| WO2006129623A1 (ja) | 2005-05-30 | 2006-12-07 | Mitsubishi Tanabe Pharma Corporation | チエノトリアゾロジアゼピン化合物及びその医薬としての用途 |
| PT2118074E (pt) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compostos para a prevenção e tratamento de doenças cardiovasculares |
| CN101910182B (zh) | 2007-12-28 | 2013-07-17 | 田边三菱制药株式会社 | 抗癌剂 |
| JP5640208B2 (ja) * | 2008-01-24 | 2014-12-17 | パナセア バイオテック リミテッド | 新規複素環化合物 |
| US8114995B2 (en) | 2008-06-26 | 2012-02-14 | Resverlogix Corp. | Methods of preparing quinazolinone derivatives |
| US20110136790A1 (en) * | 2008-07-23 | 2011-06-09 | De Lera Ruiz Manuel | Tricyclic Heterocyclic Derivatives and Methods of Use |
| US9757368B2 (en) | 2009-04-22 | 2017-09-12 | Resverlogix Corp. | Anti-inflammatory agents |
| DE102009051823A1 (de) | 2009-11-04 | 2011-05-05 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Einkristallines Schweißen von direktional verfestigten Werkstoffen |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| AU2010317096B2 (en) | 2009-11-05 | 2015-03-26 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| CN103154246B (zh) | 2010-05-14 | 2015-11-25 | 达那-法伯癌症研究所 | 用于治疗白血病的组合物和方法 |
| ES2606958T3 (es) | 2010-05-14 | 2017-03-28 | Dana-Farber Cancer Institute, Inc. | Compuestos de tienotriazolodiazepina para tratar una neoplasia |
| JP5715241B2 (ja) * | 2010-05-14 | 2015-05-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法 |
| WO2011143651A1 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating metabolism |
| EP2585465B1 (en) | 2010-06-22 | 2014-11-12 | GlaxoSmithKline LLC | Benzotriazolodiazepine compounds inhibitors of bromodomains |
| WO2012075456A1 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| EP2677865A4 (en) | 2011-02-23 | 2015-04-22 | Icahn School Med Mount Sinai | BROMODOMAIN INHIBITORS AS MODULATORS OF GENE EXPRESSION |
| WO2012151512A2 (en) | 2011-05-04 | 2012-11-08 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| WO2012174487A2 (en) | 2011-06-17 | 2012-12-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| GB201114103D0 (en) | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
| WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2013033268A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bivalent bromodomain ligands, and methods of using same |
| DE102011082013A1 (de) | 2011-09-01 | 2013-03-07 | Bayer Pharma AG | 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine |
| WO2013064231A1 (en) * | 2011-10-31 | 2013-05-10 | Phenex Pharmaceuticals Ag | SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3) |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| US20130281399A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| WO2013155695A1 (en) | 2012-04-20 | 2013-10-24 | Abbott Laboratories | Isoindolone derivatives |
| HK1208681A1 (en) | 2012-06-12 | 2016-03-11 | Abbvie Inc. | Pyridinone and pyridazinone derivatives |
| CA2901805A1 (en) * | 2013-02-22 | 2014-08-28 | Bayer Pharma Aktiengesellschaft | 4-substituted pyrrolo- and pyrazolo-diazepines |
| EP2970312B1 (en) | 2013-03-11 | 2017-11-15 | The Regents of The University of Michigan | Bet bromodomain inhibitors and therapeutic methods using the same |
| EP4649963A3 (en) | 2014-04-14 | 2026-05-13 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| GB201504314D0 (en) | 2015-03-13 | 2015-04-29 | Univ Dundee | Small molecules |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| WO2019084026A1 (en) | 2017-10-24 | 2019-05-02 | Genentech, Inc. | (4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE |
| WO2019246430A1 (en) | 2018-06-21 | 2019-12-26 | Foghorn Therapeutics Inc. | Methods of treating disorders |
| EP3814380A4 (en) | 2018-06-29 | 2022-06-15 | Dana Farber Cancer Institute, Inc. | BISPECIFIC DEGRADATION PRODUCTS |
| US12030892B2 (en) | 2018-06-29 | 2024-07-09 | Dana-Farber Cancer Institute, Inc. | CRBN modulators |
| US11542273B2 (en) | 2018-07-04 | 2023-01-03 | Mitsubishi Tanabe Pharma Corporation | Amide compound having bet proteolysis-inducing action and medicinal application thereof |
| WO2020018788A1 (en) | 2018-07-20 | 2020-01-23 | Dana-Farber Cancer Institute, Inc. | Degraders that target proteins via keap1 |
-
2017
- 2017-02-15 CA CA3014644A patent/CA3014644A1/en active Pending
- 2017-02-15 US US16/077,844 patent/US11548899B2/en active Active
- 2017-02-15 AU AU2017219627A patent/AU2017219627B2/en not_active Ceased
- 2017-02-15 WO PCT/US2017/017848 patent/WO2017142881A1/en not_active Ceased
- 2017-02-15 JP JP2018543139A patent/JP6967522B2/ja not_active Expired - Fee Related
- 2017-02-15 EP EP17708046.2A patent/EP3416969B1/en active Active
- 2017-02-15 CN CN201780023735.8A patent/CN109071562B/zh not_active Expired - Fee Related
- 2017-02-15 ES ES17708046T patent/ES2882066T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111601593B (zh) | P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd | |
| Farooqui et al. | COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia | |
| Kotiyal et al. | Breast cancer stem cells, EMT and therapeutic targets | |
| Ping et al. | The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell‐mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling | |
| US8513266B2 (en) | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha | |
| Zhang et al. | A Notch1–neuregulin1 autocrine signaling loop contributes to melanoma growth | |
| Perez-Pinera et al. | The Trk tyrosine kinase inhibitor K252a regulates growth of lung adenocarcinomas | |
| JP6967522B2 (ja) | Ｂｅｔブロモドメイン阻害剤としての融合１，４−オキサゼピンおよび関連類似体 | |
| ES2546656T3 (es) | Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas para el tratamiento de mieloma | |
| Saki et al. | Acquired resistance to cetuximab is associated with the overexpression of Ras family members and the loss of radiosensitization in head and neck cancer cells | |
| KR20120065430A (ko) | 벤즈옥세핀 ｐｉ3ｋ 억제제 화합물 및 사용 방법 | |
| WO2013072392A1 (en) | Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the janus kinase 2-signal transducer and activator of transcription 5 pathway | |
| EP2976086B1 (en) | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase | |
| EP3378476A1 (en) | H4 receptor inhibitors for treating tinnitus | |
| JP2013511560A (ja) | チロシンキナーゼインヒビターに対する感受性を増加する方法と組成物 | |
| JP2017527577A5 (enExample) | ||
| Son et al. | Synergistic Inhibitory Effects of Cetuximab and Cisplatin on Human Colon Cancer Cell Growth via Inhibition of the ERK‐Dependent EGF Receptor Signaling Pathway | |
| Li et al. | TRPV3 promotes the angiogenesis through HIF-1α-VEGF signaling pathway in A549 cells | |
| CA2983010A1 (en) | Methods for treating cancer | |
| AU2011234644B2 (en) | PKC inhibitors for the treatment of B-cell lymphoma having chronic active B-cell-receptor signalling | |
| US20180177776A1 (en) | Compositions for the treatment of cancer and uses thereof | |
| Moschos et al. | The angiopoietin/Tie2 axis mediates malignant pleural effusion formation | |
| Peng et al. | Potential role of remimazolam in alleviating bone cancer pain in mice via modulation of translocator protein in spinal astrocytes | |
| WO2023091932A1 (en) | Cancer treatment using lsd1 inhibitors and plk1 inhibitors | |
| Wang et al. | Stable gene-silence of Kif2a synergistic with 5-fluorouracil suppresses oral tongue squamous cell carcinoma growth in vitro and in vivo |